Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 14, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: November 10, 2005
- Previous Holdings: 18,453,580 ADRs
- New Holdings: 18,424,549 ADRs
- Average Price: $52.63
- Net Change: Decrease of 29,031 ADRs
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was executed as a result of a movement in the fund, which is a discretionary fund for employees and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- Verify the impact of the 29,031 ADR reduction on the total beneficial ownership of the Plan.
- Confirm the specific roles of Dr. J P Garnier and Dr. T Yamada regarding their potential interest in the fund.
- Note that this filing is a compliance notification under Disclosure Rule 3.1.4R(1)(b) and does not reflect operational or strategic changes to the company.